JP2020530289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530289A5 JP2020530289A5 JP2020506222A JP2020506222A JP2020530289A5 JP 2020530289 A5 JP2020530289 A5 JP 2020530289A5 JP 2020506222 A JP2020506222 A JP 2020506222A JP 2020506222 A JP2020506222 A JP 2020506222A JP 2020530289 A5 JP2020530289 A5 JP 2020530289A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- item
- sequence
- molecule
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022118008A JP2022145720A (ja) | 2017-07-31 | 2022-07-25 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2024053368A JP7690085B2 (ja) | 2017-07-31 | 2024-03-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2025088950A JP2025116106A (ja) | 2017-07-31 | 2025-05-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539527P | 2017-07-31 | 2017-07-31 | |
| US62/539,527 | 2017-07-31 | ||
| PCT/US2018/044449 WO2019027935A1 (en) | 2017-07-31 | 2018-07-30 | ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118008A Division JP2022145720A (ja) | 2017-07-31 | 2022-07-25 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530289A JP2020530289A (ja) | 2020-10-22 |
| JP2020530289A5 true JP2020530289A5 (enExample) | 2021-09-09 |
| JP7113071B2 JP7113071B2 (ja) | 2022-08-04 |
Family
ID=65233024
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506222A Active JP7113071B2 (ja) | 2017-07-31 | 2018-07-30 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2022118008A Withdrawn JP2022145720A (ja) | 2017-07-31 | 2022-07-25 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2024053368A Active JP7690085B2 (ja) | 2017-07-31 | 2024-03-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2025088950A Pending JP2025116106A (ja) | 2017-07-31 | 2025-05-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022118008A Withdrawn JP2022145720A (ja) | 2017-07-31 | 2022-07-25 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2024053368A Active JP7690085B2 (ja) | 2017-07-31 | 2024-03-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| JP2025088950A Pending JP2025116106A (ja) | 2017-07-31 | 2025-05-28 | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20190062448A1 (enExample) |
| EP (1) | EP3661966A4 (enExample) |
| JP (4) | JP7113071B2 (enExample) |
| KR (2) | KR20240153413A (enExample) |
| CN (2) | CN111448211B (enExample) |
| AR (1) | AR112639A1 (enExample) |
| AU (1) | AU2018312251B2 (enExample) |
| BR (1) | BR112020002012A8 (enExample) |
| CA (1) | CA3071540A1 (enExample) |
| CL (1) | CL2020000281A1 (enExample) |
| CO (1) | CO2020001983A2 (enExample) |
| CR (1) | CR20200101A (enExample) |
| DO (1) | DOP2020000021A (enExample) |
| IL (2) | IL316357A (enExample) |
| MX (1) | MX2020001270A (enExample) |
| MY (1) | MY202018A (enExample) |
| PE (1) | PE20200617A1 (enExample) |
| PH (1) | PH12020500240A1 (enExample) |
| SG (2) | SG11202000820PA (enExample) |
| TW (2) | TW202344516A (enExample) |
| WO (1) | WO2019027935A1 (enExample) |
| ZA (1) | ZA202000608B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009095478A1 (en) | 2008-01-31 | 2009-08-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| KR102584011B1 (ko) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | 암 치료를 위한 조성물 및 방법 |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| BR122022000386B1 (pt) * | 2018-03-14 | 2022-09-27 | Surface Oncology, Inc | Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| MX2020011588A (es) | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| PT3807316T (pt) | 2018-06-18 | 2024-07-29 | Innate Pharma | Composições e métodos para tratamento de cancro |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| AU2020225542A1 (en) * | 2019-02-21 | 2021-09-30 | Trishula Therapeutics, Inc. | Combination therapy involving anti-CD39 antibodies and anti-PD-1 or anti-PD-L1 antibodies |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| US12098212B2 (en) * | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
| AU2020286284B2 (en) | 2019-08-27 | 2023-11-09 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-CD39 antibodies |
| TW202124444A (zh) * | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗ｃｄ３９抗體組合物及方法 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| TW202118791A (zh) | 2019-11-05 | 2021-05-16 | 大陸商北京加科思新藥研發有限公司 | 對cd39具有特異性的結合分子及其用途 |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| KR20230019414A (ko) * | 2020-04-03 | 2023-02-08 | 트리슐라 테라퓨틱스, 인코포레이티드 | 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법 |
| TW202216768A (zh) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| WO2021260966A1 (ja) * | 2020-06-25 | 2021-12-30 | 学校法人埼玉医科大学 | アデノシン産生酵素を標的とする組成物 |
| EP4232071A4 (en) * | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| KR20230113752A (ko) * | 2020-11-27 | 2023-08-01 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | Cd39 및 tgf베타를 표적화하는 신규 접합체 분자 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| KR20240024829A (ko) | 2021-05-19 | 2024-02-26 | 애셔 바이오테라퓨틱스, 인크. | Il-21 폴리펩타이드 및 표적화된 작제물 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN118715243A (zh) * | 2022-01-24 | 2024-09-27 | 上海华奥泰生物药业股份有限公司 | Cd39抗原结合蛋白及其应用 |
| KR20240156633A (ko) * | 2022-03-03 | 2024-10-30 | 아르커스 바이오사이언시즈 인코포레이티드 | 항-cd39 항체 및 이의 용도 |
| WO2023164872A1 (en) * | 2022-03-03 | 2023-09-07 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
| JP2025507017A (ja) * | 2022-03-04 | 2025-03-13 | トリシュラ セラピューティクス， インコーポレイテッド | 胃がんにおける抗ヒトｃｄ３９抗体、抗ヒトｐｄ－１抗体、及び化学療法による併用 |
| EP4506457A1 (en) * | 2022-03-25 | 2025-02-12 | Brightpath Biotherapeutics Co., Ltd. | Anti-cd39 antibody |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2024030956A2 (en) * | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| WO2024175760A1 (en) * | 2023-02-24 | 2024-08-29 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| CN116589584B (zh) * | 2023-05-24 | 2025-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| KR102879536B1 (ko) * | 2023-06-09 | 2025-10-31 | 주식회사 브이티 | 시카 추출물이 함침된 마이크로 니들을 유효성분으로 포함하는 화장료 조성물 및 이의 제조방법 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026039538A1 (en) * | 2024-08-14 | 2026-02-19 | Trishula Therapeutics, Inc. | Methods of treating pancreatic tumors expressing certain biomarkers |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186745T1 (de) | 1995-01-18 | 1999-12-15 | Roche Diagnostics Gmbh | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern |
| AU5265296A (en) | 1995-04-10 | 1996-10-30 | Universite De Sherbrooke | Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology |
| US6387645B1 (en) | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6447771B1 (en) | 1999-03-19 | 2002-09-10 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| AU762392B2 (en) | 1998-07-16 | 2003-06-26 | Arca Biopharma, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6476211B1 (en) | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| US6899875B1 (en) | 1999-01-29 | 2005-05-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6780977B1 (en) | 1999-01-29 | 2004-08-24 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6350447B1 (en) | 1999-01-29 | 2002-02-26 | Hyseq, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6335013B1 (en) | 1999-03-19 | 2002-01-01 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| AU2002361763A1 (en) | 2001-12-17 | 2003-06-30 | Beth Israel Deaconess Medical Center | Method of reducing angiogenesis |
| US20050037382A1 (en) | 2003-04-08 | 2005-02-17 | Robson Simon C. | Methods and compositions for treating and preventing autoimmune disorders |
| WO2006111986A1 (en) | 2005-04-19 | 2006-10-26 | Fondazione Santa Lucia I.R.C.C.S. | Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof |
| CA2696263C (en) * | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
| KR20100101122A (ko) * | 2007-11-30 | 2010-09-16 | 브리스톨-마이어스 스큅 컴퍼니 | 항-ｒｇ-１ 항체의 접합체 |
| WO2009095478A1 (en) | 2008-01-31 | 2009-08-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US20130273062A1 (en) | 2010-12-22 | 2013-10-17 | Orega Biotech | Antibodies against human cd39 and use thereof |
| RU2693264C2 (ru) * | 2012-02-03 | 2019-07-01 | Ф.Хоффман-Ля Рош Аг | Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине |
| HUE054471T2 (hu) * | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Immunmodulációs módszerek és készítmények |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| WO2016191703A2 (en) | 2015-05-27 | 2016-12-01 | The Trustees Of Columbia University In The City Of New York | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer |
| KR20180068990A (ko) * | 2015-10-01 | 2018-06-22 | 포텐자 테라퓨틱스, 인코포레이티드 | 항-tigit 항체-결합 단백질 및 이의 사용 방법 |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| US20190153113A1 (en) | 2015-11-23 | 2019-05-23 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
| EP3744348B1 (en) | 2016-05-06 | 2022-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| EP3558998A4 (en) | 2016-12-22 | 2020-06-10 | Calithera Biosciences, Inc. | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE |
| KR102584011B1 (ko) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | 암 치료를 위한 조성물 및 방법 |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| BR112020006809A2 (pt) | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
| BR122022000386B1 (pt) | 2018-03-14 | 2022-09-27 | Surface Oncology, Inc | Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos |
| US12098212B2 (en) | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
| AU2020286284B2 (en) | 2019-08-27 | 2023-11-09 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-CD39 antibodies |
| TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗ｃｄ３９抗體組合物及方法 |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
-
2018
- 2018-07-30 SG SG11202000820PA patent/SG11202000820PA/en unknown
- 2018-07-30 PE PE2020000166A patent/PE20200617A1/es unknown
- 2018-07-30 US US16/049,736 patent/US20190062448A1/en not_active Abandoned
- 2018-07-30 MY MYPI2020000520A patent/MY202018A/en unknown
- 2018-07-30 EP EP18841649.9A patent/EP3661966A4/en active Pending
- 2018-07-30 KR KR1020247034153A patent/KR20240153413A/ko active Pending
- 2018-07-30 JP JP2020506222A patent/JP7113071B2/ja active Active
- 2018-07-30 AU AU2018312251A patent/AU2018312251B2/en active Active
- 2018-07-30 CN CN201880064027.3A patent/CN111448211B/zh active Active
- 2018-07-30 MX MX2020001270A patent/MX2020001270A/es unknown
- 2018-07-30 IL IL316357A patent/IL316357A/en unknown
- 2018-07-30 IL IL272367A patent/IL272367B2/en unknown
- 2018-07-30 BR BR112020002012A patent/BR112020002012A8/pt unknown
- 2018-07-30 SG SG10202111869SA patent/SG10202111869SA/en unknown
- 2018-07-30 KR KR1020207005353A patent/KR102718932B1/ko active Active
- 2018-07-30 WO PCT/US2018/044449 patent/WO2019027935A1/en not_active Ceased
- 2018-07-30 CA CA3071540A patent/CA3071540A1/en active Pending
- 2018-07-30 CR CR20200101A patent/CR20200101A/es unknown
- 2018-07-30 US US16/635,526 patent/US11345757B2/en active Active
- 2018-07-30 CN CN202410622919.8A patent/CN118978594A/zh active Pending
- 2018-07-31 TW TW112113090A patent/TW202344516A/zh unknown
- 2018-07-31 AR ARP180102152 patent/AR112639A1/es unknown
- 2018-07-31 TW TW107126546A patent/TWI798242B/zh active
-
2020
- 2020-01-29 ZA ZA2020/00608A patent/ZA202000608B/en unknown
- 2020-01-31 PH PH12020500240A patent/PH12020500240A1/en unknown
- 2020-01-31 CL CL2020000281A patent/CL2020000281A1/es unknown
- 2020-01-31 DO DO2020000021A patent/DOP2020000021A/es unknown
- 2020-02-25 CO CONC2020/0001983A patent/CO2020001983A2/es unknown
-
2021
- 2021-09-07 US US17/468,366 patent/US20210403593A1/en not_active Abandoned
-
2022
- 2022-04-20 US US17/725,142 patent/US20220340680A1/en not_active Abandoned
- 2022-05-30 US US17/827,989 patent/US20220372163A1/en not_active Abandoned
- 2022-07-25 JP JP2022118008A patent/JP2022145720A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053368A patent/JP7690085B2/ja active Active
- 2024-09-24 US US18/895,094 patent/US20250026850A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088950A patent/JP2025116106A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530289A5 (enExample) | ||
| JP2024079809A5 (enExample) | ||
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| JP2018533371A5 (enExample) | ||
| CN107847587B (zh) | Cd30×cd16抗体与pd-1拮抗剂的联合药物 | |
| JP2022115922A5 (enExample) | ||
| TW202344516A (zh) | 抗ｃｄ３９抗體、包含抗ｃｄ３９抗體之組成物及使用抗ｃｄ３９抗體之方法 | |
| JP2020514363A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| JP2018518939A5 (enExample) | ||
| JP2025000681A (ja) | Ｂｔｌａ抗体 | |
| US12098210B2 (en) | Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies | |
| JP2022044795A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| JP2022501433A (ja) | 標的化された免疫寛容 | |
| JP2020512973A5 (enExample) | ||
| JP2019537449A5 (enExample) | ||
| US20230235064A1 (en) | Bispecific immune cell engagers with binding specificity for hla-g and another antigen | |
| US20250376491A1 (en) | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | |
| JP2024073580A (ja) | Ｂｔｌａ抗体 | |
| JPWO2020069133A5 (enExample) | ||
| US20250019411A1 (en) | T-Cell Engaging Polypeptides and Methods of Use Thereof | |
| US20240279335A1 (en) | Cd28 shedding blocking agents | |
| JPWO2022072601A5 (enExample) | ||
| JPWO2021183207A5 (enExample) | ||
| RU2019118800A (ru) | Антигенсвязывающие белки против gitr и способы их прменения |